Diagnosis and management of immune checkpoint inhibitor–associated nephrotoxicity: a position statement from the American Society of Onco-nephrology

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 4.9K citations · Full text

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Journal of Clinical Oncology · 2021 · 1.7K citations · Full text

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

Frank B. Cortazar, Kristen A. Marrone, Megan L. Troxell et al. · Kidney International · 2016 · 622 citations

Glomerular Disease, Inflammation, Urology +14

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

John A. Thompson, Bryan J. Schneider, Julie R. Brahmer et al. · Journal of the National Comprehensive Cancer Network · 2019 · 549 citations · Full text